antviral/neoplasms

BACKGROUND OF THE INVENTION (a) Field of the Invention The invention relates to the antiviral activity of leukotriene B.sub.4 (LTB.sub.4), to the use of leukotriene B.sub.4 (LTB.sub.4) as a therapeutic agent and to a method for treating viral infections caused by human and animal viruses. (b)

The present invention relates to the field of the treatment of cancer and especially involves the use of antiviral agents for the treatment of cancer. The invention relates to the treatment of virus-associated cancer, or non-virus-associated cancer. In studying various human tumor cell lines derived

The present invention relates to de novo compositions of matter for the treatment of AIDS. The present invention further relates to the de novo compositions of matter containing TNF inhibitors and antiviral agents selected from the group of reverse transcriptase inhibitors, protease inhibitors, gene

CROSS-REFERENCE TO RELATED APPLICATION This application is a National Stage entry of International Application No. PCT/EP2008/003626, filed May 6, 2008, the disclosure of the prior application is hereby incorporated in its entirety by reference. BACKGROUND OF THE INVENTION Nitric oxide (NO) is a

BACKGROUND OF THE INVENTION Field of the Invention As a result of industrial globalization, viral infection by, for example, viral hepatitis, influenza, pneumonia, encephalitis, virus-induced carcinoma and acquired immune deficiency syndrome (AIDS) is becoming an epidemic phenomenon. Virus-induced

BACKGROUND Uterine cervical cancer is a public health problem worldwide, primarily affecting women in emerging countries, Mexico included. German scientist Harald zur Hausen, awarded the Nobel Prize for Medicine in 2008, discovered the major role that the human papillomavirus has in the development

1. FIELD OF THE INVENTION The present invention is in the field supramolecular structures that specifically bind to a selected target. 2. BACKGROUND Organized molecular systems are well known in biology and chemistry. For example, pure molecular compounds form crystals, and surface active molecular

TECHNICAL FIELD The present invention generally relates to prophylactic and therapeutic agents for the prevention and treatment of viral-induced tumors, such as warts. In one embodiment, the therapeutic agent in the form of a soap, comprising natural sandalwood oil and vegetable ingredients. The

This application asserts priority from and is a National Stage of PCT Application Ser. No. PCT/GB2010/051595 filed 23 Sept. 2010, which asserts priority from Great Britain provisional patent filing Ser. No. 09/169970 filed 28 Sept. 2009, the contents of which are here incorporated by

FIELD OF THE INVENTION The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleotide analogs. More specifically, the invention describes 6-substituted-2-amino purine nucleoside monophosphate and monophosphonate prodrugs and

FIELD OF THE INVENTION The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleotide analogs. More specifically, the invention describes 6-substituted-2-amino purine nucleoside monophosphate and monophosphonate prodrugs and

TECHNICAL FIELD The present invention generally relates to therapeutic agents for the treatment of viral-induced tumors, such as warts. In one embodiment, the therapeutic agent is in the form of sandalwood oil or an isolate or isolates from the sandalwood oil described herein. Use of the oil or its

FIELD OF THE INVENTION This invention relates to novel antiviral helioxanthin analogs. These compounds may particularly be used alone or in combination with other drugs for the treatment of the following: hepadnaviruses, flaviviruses, herpesviruses and human immunodeficiency virus. In addition,

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention provides compositions and methods for modulating cutaneous and mucocutaneous or mucosal proliferations that are benign or malignant, which are of viral origin such as common warts and plane warts. The methods and

FIELD OF THE INVENTION The subject invention relates to viruses that are able to replicate in and cause the death of neoplastic cells with a deficiency in the interferon (IFN)-mediated antiviral response. RNA and DNA viruses are useful in this regard. The invention also relates to the use of these